Nanomaterials in EU Cosmetics: The Article 16 Pre-Market Obligation Non-EU Brands Miss

Every year, brands complete their standard CPNP notification, receive confirmation, and assume their EU compliance is done. Then the Responsible Person flags a problem: the SPF50 moisturizer formula contains titanium dioxide in nano form, and there’s a separate six-month pre-market notification that should have been filed months ago.

That Article 16 obligation — the nanomaterial-specific notification under Regulation (EC) No 1223/2009 — is one of the most consistently missed compliance steps for non-EU cosmetic brands entering the European market. The CPNP portal currently lists over 1,200 individual nanomaterial notifications filed under Article 16. Yet industry experience suggests that fewer than 40% of brands from North America and Asia correctly identify their formulations as containing notifiable nanomaterials before engaging a Responsible Person. That gap is where compliance failures — and product holds — happen.

What Regulation (EC) No 1223/2009 Actually Says About Nanomaterials

Article 16 of Regulation (EC) No 1223/2009 imposes obligations specific to cosmetic products containing nanomaterials, entirely separate from the standard product dossier and CPNP submission that most brands are familiar with.

Under the regulation, a nanomaterial is defined as an insoluble or biopersistent and intentionally manufactured material with one or more external dimensions, or an internal structure, on the scale of 1 to 100 nm. That qualifier — intentionally manufactured — matters enormously during formulation review. Incidentally produced nano-sized particles, such as trace impurities from manufacturing, don’t automatically trigger Article 16. But if your ingredient supplier markets a particle as “nano” or “nanosized” for enhanced UV performance, skin penetration, or bioavailability, you must treat it as notifiable unless documented evidence supports otherwise.

The regulation also establishes a critical principle: nanomaterials must be assessed for safety in their nano form, separately from any approval that exists for the conventional (non-nano) version of the same substance. A substance that’s been toxicologically evaluated and approved at conventional particle sizes carries no automatic safety clearance into its nano form. This is precisely why titanium dioxide and zinc oxide — both long-established UV filters in Annex VI — had to be reviewed independently as [nano] variants by the Scientific Committee on Consumer Safety (SCCS) before their use conditions could be confirmed.

The 6-Month Pre-Market Notification: Why It Keeps Catching Brands Off Guard

Here’s the specific obligation that repeatedly trips up launch timelines: under Article 16(3) of Regulation (EC) No 1223/2009, cosmetic products containing nanomaterials that are not otherwise restricted or prohibited must be notified to the European Commission through the CPNP portal at least six months before being placed on the EU market.

Six months. Not the two months required for the standard product notification. Not simultaneously with launch preparations. Six calendar months before the intended market date — and that clock starts from the final, approved formulation, not from an early-stage brief.

This notification must include: the INCI and chemical name of the nanomaterial, the reasonably foreseeable exposure conditions and routes, a toxicological profile specific to the nano form, and relevant safety data. If the Commission identifies safety concerns following notification, it can refer the matter to the SCCS for a formal opinion. That process alone can take 12 to 18 months — potentially blocking the product’s launch window entirely.

For a brand planning a nano-containing SPF moisturizer for a spring retail launch, this means the Article 16 filing needs to be submitted in autumn of the prior year. Brands that miss this window face two options: delay the launch or reformulate. We’ve seen both, and neither is cheap.

And this is layered on top of the existing timeline demands. The Responsible Person must be established in the EU before any filing can occur. The Product Information File must be complete. The safety assessment by a qualified Cosmetic Product Safety Assessor (CPSA) must already address the nano-specific data. Brands that treat EU entry as a two-month process are not accounting for the reality of nano compliance.

Labeling: Getting the [nano] Designation Right Is Not Optional

Article 19(1)(g) of Regulation (EC) No 1223/2009 requires that any nanomaterial ingredient be identified in the product’s ingredient list with the word [nano] in brackets, placed immediately after the INCI name.

Titanium dioxide in nano form must therefore appear as Titanium Dioxide [nano] — not simply “Titanium Dioxide.” That distinction matters to enforcement authorities and, increasingly, to consumers evaluating nano ingredients in their personal care products.

This labeling obligation applies to all products placed on the EU market, regardless of whether they underwent an Article 16 notification. It’s not a notification-triggered requirement — it applies universally wherever the nano form is present. We regularly encounter incorrect ingredient listings on products entering France through e-commerce channels, where the country-of-origin labeling used the conventional INCI name without the [nano] designation. The DGCCRF (Direction générale de la concurrence, de la consommation et de la répression des fraudes), France’s consumer goods enforcement authority, has cited unlabeled nanomaterials in its annual cosmetics market surveillance reports and conducts targeted inspections specifically covering nanomaterial labeling.

France is, consistently, one of the EU’s more active enforcement jurisdictions for cosmetics. If your distribution hub is Paris — as it is for many beauty brands entering Europe — getting the nano labeling right from day one is basic risk management.

The Ingredients Under the Most Scrutiny Right Now

Not all nanomaterials carry equal regulatory weight. These are the ones generating the most compliance questions in practice:

Titanium Dioxide [nano]: The most widely used nano UV filter in physical sunscreens and SPF cosmetics. The SCCS issued its final opinion (SCCS/1617/20) confirming its safety for use on healthy, intact skin at concentrations up to 25% — but specifically excluding spray and powder formats where inhalation exposure is a realistic route. The Commission subsequently formalized a prohibition on TiO2 [nano] in spray and aerosol product categories. If your product is an SPF setting spray, aerosol sunscreen, or any nano-TiO2-containing powder cosmetic, it cannot legally enter EU commerce in that form.

Zinc Oxide [nano]: Permitted as a UV filter at concentrations up to 25% in non-spray, non-mucous membrane skin applications. The SCCS confirmed its safety for face and body lotions under these specific conditions. It remains prohibited in spray applications that risk inhalation exposure near mucous membranes. The safety basis explicitly does not extend to oral or periocular area applications.

Carbon Black [nano] (CI 77266): This one catches formulators working with black pigments completely off guard. Conventional carbon black (CI 77266) has specific permitted uses in eye-area products under Annex IV. But carbon black [nano] appears in Annex II — the list of prohibited substances — full stop, with no permitted uses. If a pigment supplier is providing a nanosized-grade carbon black, that ingredient cannot lawfully appear in any EU cosmetic product, regardless of the application type or concentration.

Silica [nano] (hydrated): The SCCS reviewed hydrated silica in nano form and found it acceptable at concentrations typical of cosmetic use in rinse-off dental products and certain skin applications. But the opinion is formulation-specific, and silica nano from different manufacturing routes may not share the same safety profile. Supplier documentation confirming particle dimensions and surface treatment is essential before relying on this SCCS opinion for your specific ingredient.

Hydroxyapatite [nano]: A growing ingredient in remineralizing toothpastes and certain skincare claims. The SCCS concluded it’s safe in toothpaste at concentrations up to 10% — but only for rod-shaped particles meeting specific dimensional parameters. Nano hydroxyapatite of other morphologies, needle-like particles in particular, was explicitly not covered by that opinion. This is the kind of nuance that creates a compliance gap when a “nano HA” ingredient certificate of analysis doesn’t specify particle geometry.

What Non-EU Brands Need to Do Before Their Product Reaches the EU Market

If your formulation contains any of the ingredients above — or any ingredient marketed by your supplier as “nano” for performance reasons — here’s the practical compliance sequence before EU launch:

1. Audit your formula against particle size data: Review every ingredient’s technical data sheet for particle size specifications. Suppliers marketing enhanced UV performance or bioavailability at the nano scale will typically disclose this in their technical dossiers, though not always prominently in standard safety data sheets.

2. Confirm the regulatory status of each nanomaterial: Determine whether the ingredient is prohibited (Annex II), restricted with conditions (Annexes III–VI), permitted following a specific SCCS opinion, or not yet reviewed — and therefore subject to the Article 16 pre-notification pathway.

3. File the Article 16 notification no later than 6 months before your target launch date: This filing is managed through the CPNP portal and must be submitted by the EU Responsible Person. If you do not yet have an RP arrangement in place, that agreement must be formalized before this clock starts.

4. Update all pack ingredient labeling: Ensure every product format — primary pack, secondary pack, and e-commerce product pages used as primary packaging substitutes — carries the [nano] designation in the ingredient list. This includes reformulations of existing products if the nano form is newly introduced.

5. Commission a nano-specific safety assessment section for the PIF: Your CPSA must address the nano form of each notifiable ingredient explicitly — covering particle size distribution, surface treatment or coating, relevant exposure routes, and nano-specific toxicological data. A reference to the conventional substance’s safety data is insufficient on its own.

The compliance failure mode here is almost never ignorance of the rules. It’s underestimating the timeline. EU entry with a nano-containing cosmetic product requires a minimum of eight to ten months of lead time from formula finalization, accounting for RP establishment, safety assessment, Article 16 filing, and the standard product notification. Brands that plan for two months face a choice between delay and non-compliance.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Care Europe | VP Operations, Qalitex. Learn more about our team

Talk to our team about EU market entry Contact us

Related from our network

• Cosmetic Ingredient and Formulation Testing to Support EU PIF Documentation — Qalitex Laboratories provides ISO 17025 accredited analytical testing for cosmetic ingredients, including particle size characterization and safety testing relevant to EU Regulation 1223/2009 compliance.
• NHP and Cosmetic Product Testing for Brands Expanding Between Canadian and EU Markets — Androxa supports Health Canada NHP compliance and cosmetic ingredient testing for brands navigating both Canadian and European regulatory requirements.